This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhou, Z. Articles by Tryggvason, K. Search for Related Content PubMed PubMed Citation Articles by Zhou, Z. Articles by Tryggvason, K.

Impaired Angiogenesis, Delayed Wound Healing and Retarded Tumor Growth in Perlecan Heparan Sulfate-Deficient Mice

¹ Department of Biochemistry, Faculty of Medicine, University of Hong Kong, Hong Kong; ² Division of Matrix Biology, Department of Medical Biochemistry and Biophysics, and ³ Microbiology and Tumorbiology Center, Karolinska Institute, Stockholm, Sweden; ⁴ Institute of Molecular Medicine, Department of Medicine, University of California at San Diego, La Jolla, California; and ⁵ Department of Medical Biochemistry and Molecular Biology, University of Oulu, Oulu, Finland

Perlecan, a modular proteoglycan carrying primary heparan sulfate (HS) side chains, is a major component of blood vessel basement membranes. It sequesters growth factors such as fibroblast growth factor 2 (FGF-2) and regulates the ligand-receptor interactions on the cell surface, and thus it has been implicated in the control of angiogenesis. Both stimulatory and inhibitory effects of perlecan on FGF-2 signaling have been reported. To understand the in vivo function of HS carried by perlecan, the perlecan gene heparan sulfate proteoglycan 2 (Hspg2) was mutated in mouse by gene targeting. The HS at the NH₂ terminus of perlecan was removed while the core protein remained intact. Perlecan HS-deficient (Hspg2^3/3) mice survived embryonic development and were apparently healthy as adults. However, mutant mice exhibited significantly delayed wound healing, retarded FGF-2-induced tumor growth, and defective angiogenesis. In the mouse corneal angiogenesis model, FGF-2-induced neovascularization was significantly impaired in Hspg2^3/3 mutant mice. Our results suggest that HS in perlecan positively regulates the angiogenesis in vivo.

This article has been cited by other articles:

				Y. Suarez, C. Fernandez-Hernando, J. Yu, S. A. Gerber, K. D. Harrison, J. S. Pober, M. L. Iruela-Arispe, M. Merkenschlager, and W. C. Sessa Dicer-dependent endothelial microRNAs are necessary for postnatal angiogenesis PNAS, September 16, 2008; 105(37): 14082 - 14087. [Abstract] [Full Text] [PDF]

				J. J. Zoeller, A. McQuillan, J. Whitelock, S.-Y. Ho, and R. V. Iozzo A central function for perlecan in skeletal muscle and cardiovascular development J. Cell Biol., April 21, 2008; 181(2): 381 - 394. [Abstract] [Full Text] [PDF]

				M. Gotte, D. Spillmann, G. W. Yip, E. Versteeg, F. G. Echtermeyer, T. H. van Kuppevelt, and L. Kiesel Changes in heparan sulfate are associated with delayed wound repair, altered cell migration, adhesion and contractility in the galactosyltransferase I (ss4GalT-7) deficient form of Ehlers-Danlos syndrome Hum. Mol. Genet., April 1, 2008; 17(7): 996 - 1009. [Abstract] [Full Text] [PDF]

				J. W.A.M. Celie, N. W.P. Rutjes, E. D. Keuning, R. Soininen, R. Heljasvaara, T. Pihlajaniemi, A. M. Drager, S. Zweegman, F. L. Kessler, R. H.J. Beelen, et al. Subendothelial Heparan Sulfate Proteoglycans Become Major L-Selectin and Monocyte Chemoattractant Protein-1 Ligands upon Renal Ischemia/Reperfusion Am. J. Pathol., June 1, 2007; 170(6): 1865 - 1878. [Abstract] [Full Text] [PDF]

				M. M. Fuster, L. Wang, J. Castagnola, L. Sikora, K. Reddi, P. H.A. Lee, K. A. Radek, M. Schuksz, J. R. Bishop, R. L. Gallo, et al. Genetic alteration of endothelial heparan sulfate selectively inhibits tumor angiogenesis J. Cell Biol., May 7, 2007; 177(3): 539 - 549. [Abstract] [Full Text] [PDF]

				K. D. Rodgers, T. Sasaki, A. Aszodi, and O. Jacenko Reduced perlecan in mice results in chondrodysplasia resembling Schwartz-Jampel syndrome Hum. Mol. Genet., March 1, 2007; 16(5): 515 - 528. [Abstract] [Full Text] [PDF]

				G. Bix, R. Castello, M. Burrows, J. J. Zoeller, M. Weech, R. A. Iozzo, C. Cardi, M. L. Thakur, C. A. Barker, K. Camphausen, et al. Endorepellin In Vivo: Targeting the Tumor Vasculature and Retarding Cancer Growth and Metabolism. J Natl Cancer Inst, November 15, 2006; 98(22): 1634 - 1646. [Abstract] [Full Text] [PDF]

				G. W. Yip, M. Smollich, and M. Gotte Therapeutic value of glycosaminoglycans in cancer. Mol. Cancer Ther., September 1, 2006; 5(9): 2139 - 2148. [Abstract] [Full Text] [PDF]

				I. Sher, S. Zisman-Rozen, L. Eliahu, J. M. Whitelock, N. Maas-Szabowski, Y. Yamada, D. Breitkreutz, N. E. Fusenig, E. Arikawa-Hirasawa, R. V. Iozzo, et al. Targeting Perlecan in Human Keratinocytes Reveals Novel Roles for Perlecan in Epidermal Formation J. Biol. Chem., February 24, 2006; 281(8): 5178 - 5187. [Abstract] [Full Text] [PDF]

				A.A. DeCarlo and J.M. Whitelock The Role of Heparan Sulfate and Perlecan in Bone-regenerative Procedures Journal of Dental Research, February 1, 2006; 85(2): 122 - 132. [Abstract] [Full Text] [PDF]

				H. Morita, A. Yoshimura, K. Inui, T. Ideura, H. Watanabe, L. Wang, R. Soininen, and K. Tryggvason Heparan Sulfate of Perlecan Is Involved in Glomerular Filtration J. Am. Soc. Nephrol., June 1, 2005; 16(6): 1703 - 1710. [Abstract] [Full Text] [PDF]

				E. M. Gonzalez, C. C. Reed, G. Bix, J. Fu, Y. Zhang, B. Gopalakrishnan, D. S. Greenspan, and R. V. Iozzo BMP-1/Tolloid-like Metalloproteases Process Endorepellin, the Angiostatic C-terminal Fragment of Perlecan J. Biol. Chem., February 25, 2005; 280(8): 7080 - 7087. [Abstract] [Full Text] [PDF]